Hester Biosciences Ltd share Price Today

Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania.

• It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products
• Sales break-up for Q3FY23: Poultry healthcare: 42%, Animal healthcare: 58%

Animal healthcare boosted revenues, gross margins impacted due to stock write off.

• Sales were up 34.6% YoY to ₹ 75 crore
• EBITDA was at ₹ 19 crore, up 24.9%, with margins at 25%
• Adjusted PAT was at ₹ 12.3 crore (up 45% YoY)

Pharmaceuticals company Hester Biosciences announced Q4FY24 & FY24 results:

Financial Highlights:

• Hester Biosciences reported an increase in standalone revenue by 20% and consolidated revenue by 18% in Q4FY24 compared to the previous year.
• The audited financial results for Q4 & FY24 show the company's resilience with a recommendation for a dividend of 6 per equity share of Rs 10 each (60%) for FY24, awaiting shareholder approval.
• The company has reduced its borrowing by 19% and increased cash generated from operations by 28% during the year.
• Overall gross profit margin in Q4FY24 increased by 1% compared to Q4FY23, primarily due to the increase in the proportion of vaccines from 60% to 75% in Q4FY24.
• In Q4FY24, EBITDA increased by 14% in alignment with a growth in sales, resulting in a 19% increase in PAT for the quarter.
• The total borrowings of the Company has reduced by Rs 307.58 million (19%) during the year.
• The cash generated from operations has increased by Rs 94.50 million (28%) during the year

Animal Healthcare Division:

• The Animal Healthcare division saw a growth of 89% in Q4FY24, driven by sales of Goat Pox vaccine and vaccines for a government immunisation program.
• Despite regulatory challenges, the Animal Healthcare division has demonstrated the ability to recover and sustain growth.

Poultry Healthcare Division:

• The Poultry Healthcare division achieved a notable growth of 22% in Q4FY24, with a consistent upward trend throughout the year.
• Strategic introductions of new products and leveraging market opportunities have been instrumental in the division's sales performance.

Petcare Division:

• In Q4FY24, the Petcare division saw a minor decrease in sales from the previous quarter but reported a notable annual growth of 49%.
• The Petcare division's focus on building a strong foundation and delivering high-quality products is reflected in its substantial growth. 

Result PDF